| 臺大學術典藏 |
2022-02-21T03:52:37Z |
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
|
Soh S.X.; Siddiqui F.J.; Allen J.C.; Kim G.W.; Lee J.C.; Yatabe Y.; Soda M.; Mano H.; Soo R.A.; Chin T.-M.; Ebi H.; Yano S.; Matsuo K.; Niu X.; Lu S.; Isobe K.; JIH-HSIANG LEE; Yang J.C.; Zhao M.; Zhou C.; Lee J.-K.; Lee S.-H.; Lee J.Y.; Ahn M.-J.; Tan T.J.; Tan D.S.; Tan E.-H.; Ong S.T.; Lim W.-T. |
| 國立成功大學 |
2022 |
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Na�ve Patients with�EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China
|
Tu, H.-Y.;Feng, J.;Shi, M.;Zhao, J.;Wang, Y.;Chang, J.;Wang, J.;Cheng, Y.;Zhu, J.;Tan, E.-H.;Li, K.;Zhang, Y.;Lee, V.;Yang, C.-T.;Su, W.-C.;Lam, D.C.-L.;Srinivasa, B.J.;Rajappa, S.;Ho, C.-L.;Lam, K.C.;Hu, Y.;Bondarde, S.A.;Liu, X.;Tian, Y.;Xue, Z.;Cseh, A.;Huang, D.C.-L.;Zhou, C.;Wu, Y.-L. |
| 臺大學術典藏 |
2021-07-13T06:04:35Z |
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
|
Soh S.X.; Siddiqui F.J.; Allen J.C.; Kim G.W.; Lee J.C.; Yatabe Y.; Soda M.; Mano H.; Soo R.A.; Chin T.-M.; Ebi H.; Yano S.; Matsuo K.; Niu X.; Lu S.; Isobe K.; LEE JIH-HSIANG; Yang J.C.; Zhao M.; Zhou C.; Lee J.-K.; Lee S.-H.; Lee J.Y.; Ahn M.-J.; Tan T.J.; Tan D.S.; Tan E.-H.; Ong S.T.; Lim W.-T. |
| 臺大學術典藏 |
2020-12-02T02:34:19Z |
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer
|
Tan E.-H.;Ramlau R.;Pluzanska A.;Kuo H.-P.;Reck M.;Milanowski J.;Au J.S.-K.;Felip E.;Pan-Chyr Yang;Damyanov D.;Orlov S.;Akimov M.;Delmar P.;Essioux L.;Hillenbach C.;Klughammer B.;Mcloughlin P.;Baselga J.; Tan E.-H.; Ramlau R.; Pluzanska A.; Kuo H.-P.; Reck M.; Milanowski J.; Au J.S.-K.; Felip E.; PAN-CHYR YANG; Damyanov D.; Orlov S.; Akimov M.; Delmar P.; Essioux L.; Hillenbach C.; Klughammer B.; McLoughlin P.; Baselga J. |
| 臺大學術典藏 |
2020-05-26T09:27:27Z |
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study
|
Botwood N; Thatcher N.; Watkins C; Tsao C.-J; CHIH-HSIN YANG; Ganzon D; Perng R.-P; Tan E.H; Thongprasert S; Parikh P; Chang A; Chang A;Parikh P;Thongprasert S;Tan E.H;Perng R.-P;Ganzon D;Chih-Hsin Yang;Tsao C.-J;Watkins C;Botwood N;Thatcher N. |
| 臺大學術典藏 |
2020-05-26T09:27:27Z |
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study
|
Botwood N; Thatcher N.; Watkins C; Tsao C.-J; CHIH-HSIN YANG; Ganzon D; Perng R.-P; Tan E.H; Thongprasert S; Parikh P; Chang A; Chang A;Parikh P;Thongprasert S;Tan E.H;Perng R.-P;Ganzon D;Chih-Hsin Yang;Tsao C.-J;Watkins C;Botwood N;Thatcher N. |
| 臺大學術典藏 |
2020-05-26T09:27:15Z |
Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer
|
Hensing T; Lee C; Gupta N; Pradhan R; Qian J; Qin Q; Scappaticci F.A; Ricker J.L; Carlson D.M; Soo R.A.; Tan E.-H;Goss G.D;Salgia R;Besse B;Gandara D.R;Hanna N.H;Chih-Hsin Yang;Thertulien R;Wertheim M;Mazieres J;Hensing T;Lee C;Gupta N;Pradhan R;Qian J;Qin Q;Scappaticci F.A;Ricker J.L;Carlson D.M;Soo R.A.; Tan E.-H; Goss G.D; Salgia R; Besse B; Gandara D.R; Hanna N.H; CHIH-HSIN YANG; Thertulien R; Wertheim M; Mazieres J |
| 臺大學術典藏 |
2020-05-26T09:27:15Z |
Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer
|
Hensing T; Lee C; Gupta N; Pradhan R; Qian J; Qin Q; Scappaticci F.A; Ricker J.L; Carlson D.M; Soo R.A.; Tan E.-H;Goss G.D;Salgia R;Besse B;Gandara D.R;Hanna N.H;Chih-Hsin Yang;Thertulien R;Wertheim M;Mazieres J;Hensing T;Lee C;Gupta N;Pradhan R;Qian J;Qin Q;Scappaticci F.A;Ricker J.L;Carlson D.M;Soo R.A.; Tan E.-H; Goss G.D; Salgia R; Besse B; Gandara D.R; Hanna N.H; CHIH-HSIN YANG; Thertulien R; Wertheim M; Mazieres J |
| 臺大學術典藏 |
2020-05-26T09:27:07Z |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
|
Chih-Hsin Yang;Lorence R.M;Cong X.J;Shahidi M;Chao T.-Y;Tan E.-H;Crino L;Heo D.S;Sun Y;Wang M;Su W.-C;Zhou C;Kim S.-W;Park K;Chen Y.-M;Cadranel J;Hirsh V;Miller V.A; Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:07Z |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
|
Chih-Hsin Yang;Lorence R.M;Cong X.J;Shahidi M;Chao T.-Y;Tan E.-H;Crino L;Heo D.S;Sun Y;Wang M;Su W.-C;Zhou C;Kim S.-W;Park K;Chen Y.-M;Cadranel J;Hirsh V;Miller V.A; Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:03Z |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
|
Lee C.K;Brown C;Gralla R.J;Hirsh V;Thongprasert S;Tsai C.-M;Tan E.H;Ho J.C.-M;Chu D.T;Zaatar A;Osorio Sanchez J.A;Vu V.V;Au J.S.K;Inoue A;Lee S.M;Gebski V;Chih-Hsin Yang; Lee C.K; Brown C; Gralla R.J; Hirsh V; Thongprasert S; Tsai C.-M; Tan E.H; Ho J.C.-M; Chu D.T; Zaatar A; Osorio Sanchez J.A; Vu V.V; Au J.S.K; Inoue A; Lee S.M; Gebski V; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:03Z |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
|
Lee C.K;Brown C;Gralla R.J;Hirsh V;Thongprasert S;Tsai C.-M;Tan E.H;Ho J.C.-M;Chu D.T;Zaatar A;Osorio Sanchez J.A;Vu V.V;Au J.S.K;Inoue A;Lee S.M;Gebski V;Chih-Hsin Yang; Lee C.K; Brown C; Gralla R.J; Hirsh V; Thongprasert S; Tsai C.-M; Tan E.H; Ho J.C.-M; Chu D.T; Zaatar A; Osorio Sanchez J.A; Vu V.V; Au J.S.K; Inoue A; Lee S.M; Gebski V; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:51Z |
A randomized phase 2 study comparing the combination of ficlatuzumab and gefitinib with gefitinib alone in asian patients with advanced stage pulmonary adenocarcinoma
|
Park K.;Close S;Garrus J.E;Payumo F;Komarnitsky P;Han M;Chang G.-C;Chih-Hsin Yang;Tan E.-H;Su W.-C;Geater S.L;Mok T.S.K; Mok T.S.K; Geater S.L; Su W.-C; Tan E.-H; CHIH-HSIN YANG; Chang G.-C; Han M; Komarnitsky P; Payumo F; Garrus J.E; Close S; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:51Z |
A randomized phase 2 study comparing the combination of ficlatuzumab and gefitinib with gefitinib alone in asian patients with advanced stage pulmonary adenocarcinoma
|
Park K.;Close S;Garrus J.E;Payumo F;Komarnitsky P;Han M;Chang G.-C;Chih-Hsin Yang;Tan E.-H;Su W.-C;Geater S.L;Mok T.S.K; Mok T.S.K; Geater S.L; Su W.-C; Tan E.-H; CHIH-HSIN YANG; Chang G.-C; Han M; Komarnitsky P; Payumo F; Garrus J.E; Close S; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:47Z |
140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
|
Mok T; Kim M; Paz-Ares L.; Paz-Ares L.;Kim M;Mok T;Chih-Hsin Yang;Boyer M;O'Byrne K;Hirsh V;Zhang L;Tan E.-H;Park K; Park K; Tan E.-H; Zhang L; Hirsh V; O'Byrne K; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:47Z |
140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
|
Mok T; Kim M; Paz-Ares L.; Paz-Ares L.;Kim M;Mok T;Chih-Hsin Yang;Boyer M;O'Byrne K;Hirsh V;Zhang L;Tan E.-H;Park K; Park K; Tan E.-H; Zhang L; Hirsh V; O'Byrne K; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:45Z |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial
|
Paz-Ares L.;Zazulina V;Massey D;Kim M;Shahidi M;Tsai C.-M;Laurie S.A;K?lbeck K;Arvis C.D;Kim D.-W;Laskin J;Kim S.-W;Shi Y;Lu S;Lee K.H;Chih-Hsin Yang;Hirsh V;Mok T;Boyer M;Zhang L;O'Byrne K;Tan E.-H;Park K; Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. |
| 臺大學術典藏 |
2020-05-26T09:26:45Z |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial
|
Paz-Ares L.;Zazulina V;Massey D;Kim M;Shahidi M;Tsai C.-M;Laurie S.A;K?lbeck K;Arvis C.D;Kim D.-W;Laskin J;Kim S.-W;Shi Y;Lu S;Lee K.H;Chih-Hsin Yang;Hirsh V;Mok T;Boyer M;Zhang L;O'Byrne K;Tan E.-H;Park K; Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
|
Lee J.C; Kim G.W; Allen J.C; Siddiqui F.J; Soh S.X; Lim W.-T.;Ong S.T;Tan E.-H;Tan D.S;Tan T.J;Ahn M.-J;Lee J.Y;Lee S.-H;Lee J.-K;Zhou C;Zhao M;Chih-Hsin Yang;Lee J.-H;Isobe K;Lu S;Niu X;Matsuo K;Yano S;Ebi H;Chin T.-M;Soo R.A;Mano H;Soda M;Yatabe Y;Lee J.C;Kim G.W;Allen J.C;Siddiqui F.J;Soh S.X; Yatabe Y; Soda M; Mano H; Soo R.A; Chin T.-M; Ebi H; Yano S; Matsuo K; Niu X; Lu S; Isobe K; Lee J.-H; CHIH-HSIN YANG; Zhao M; Zhou C; Lee J.-K; Lee S.-H; Lee J.Y; Ahn M.-J; Tan T.J; Tan D.S; Tan E.-H; Ong S.T; Lim W.-T. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
|
Lee J.C; Kim G.W; Allen J.C; Siddiqui F.J; Soh S.X; Lim W.-T.;Ong S.T;Tan E.-H;Tan D.S;Tan T.J;Ahn M.-J;Lee J.Y;Lee S.-H;Lee J.-K;Zhou C;Zhao M;Chih-Hsin Yang;Lee J.-H;Isobe K;Lu S;Niu X;Matsuo K;Yano S;Ebi H;Chin T.-M;Soo R.A;Mano H;Soda M;Yatabe Y;Lee J.C;Kim G.W;Allen J.C;Siddiqui F.J;Soh S.X; Yatabe Y; Soda M; Mano H; Soo R.A; Chin T.-M; Ebi H; Yano S; Matsuo K; Niu X; Lu S; Isobe K; Lee J.-H; CHIH-HSIN YANG; Zhao M; Zhou C; Lee J.-K; Lee S.-H; Lee J.Y; Ahn M.-J; Tan T.J; Tan D.S; Tan E.-H; Ong S.T; Lim W.-T. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
|
Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K.; Park K.;M?rten A;Dodd N;Fan J;K?lbeck K;Laurie S.A;Kim D.-W;Laskin J;Lee D.H;Shi Y;Lu S;Lee K.H;Mok T;Chih-Hsin Yang;Boyer M;Hirsh V;Zhang L;O'Byrne K;Tan E.-H;Paz-Ares L; Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
|
Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K.; Park K.;M?rten A;Dodd N;Fan J;K?lbeck K;Laurie S.A;Kim D.-W;Laskin J;Lee D.H;Shi Y;Lu S;Lee K.H;Mok T;Chih-Hsin Yang;Boyer M;Hirsh V;Zhang L;O'Byrne K;Tan E.-H;Paz-Ares L; Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|
Havel L; Pauk N; Singh J; Murakami S; Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Juat N;Hagenstad C;Einspahr D;Crin? L;Bocskei C;Page R;Levy B;Koubkova L;Khanani S;Juhasz E;Torri V;Iqbal M;Anderson I;Price A;Losonczy G;Csoszi T;Murakami S;Singh J;Pauk N;Havel L;Coupkova H;Cernovska M;Sebastian M;Schulte C;Ladrera G.E.I;Kobayashi K;Daniel D;Panwalkar A;Mohn-Staudner A;Juan Vidal O;Takeda K;Kato T;Gettinger S;Hirashima T;Tan E.H;Sugawara S;Nakagawa K;Querol J;Reynolds J;Haigentz M;Iannotti N;Boccia R;Ikeda N;Hesketh P;Giridharan S;Chaudhry A;Herzmann C;Chang G.-C;Satouchi M;Mark Z;Coudert B;Waterhouse D;Waller C;Kubota K;Vrindavanam N;Malcolm A;Palmero Sanchez R;Juergens R;Jassem J;Chachoua A;Feld R;Bradbury P;Azuma K;Kemmotsu H;Aglietta M;Scholz C;Canon J.-L;Weiss G;Bosch-Barrera J;Goto K;Vincent M;Sakai H;Denis F;Hsia T.-C;Chih-Hsin Yang;Alvarez Alvarez R;Garcia Gomez R;Chewaskulyong B;Spigel D;Chen Y.-M;Barlesi F;Kowalski D;Italiano A;Lucien Geater S;Uy M.N;Santoro A;Kubiak K;Zylla D;Maeda T;Derijcke S;Veillon R;Gabrail N;Imamura F;Nishio M;Spaeth-Schwalbe E;Atagi S;Kang E.J;Yokoi T;Sibille A;Ramos Garcia I;Milella M;Saka H;Lee J.-S;Wolf J;Kim Y.-C;Su W.-C;Katakami N;Atlantic Investigators;Szalai Z;Garrison M;Overton L;Cheema P;Thomas M;Soto Parra H;Robinet G;Chopra A;Chella A;Oe Y;Belda Iniesta C;Holgado Martin E;Han J.-Y;Reck M;Surmont V;Kim D.-W;Berghmans T;Vicente Baz D;Chaft J;Kim S.-W;Maemondo M;Califano R;Laack E;Schmid P;Hiret S;Novello S;Paz-Ares Rodriguez L;Rizvi N.A;Dennis P.A;Wadsworth C;Huang Y;Soo R.A;Park K;Wheatley-Price P;Bidoli P;Chouaid C;Powderly J;Gray J.E;Corral Jaime J;Lena H;Vansteenkiste J;Mazi?res J;Kim J.-H;Cho B.-C;Garassino M.C |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|
Havel L; Pauk N; Singh J; Murakami S; Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Juat N;Hagenstad C;Einspahr D;Crin? L;Bocskei C;Page R;Levy B;Koubkova L;Khanani S;Juhasz E;Torri V;Iqbal M;Anderson I;Price A;Losonczy G;Csoszi T;Murakami S;Singh J;Pauk N;Havel L;Coupkova H;Cernovska M;Sebastian M;Schulte C;Ladrera G.E.I;Kobayashi K;Daniel D;Panwalkar A;Mohn-Staudner A;Juan Vidal O;Takeda K;Kato T;Gettinger S;Hirashima T;Tan E.H;Sugawara S;Nakagawa K;Querol J;Reynolds J;Haigentz M;Iannotti N;Boccia R;Ikeda N;Hesketh P;Giridharan S;Chaudhry A;Herzmann C;Chang G.-C;Satouchi M;Mark Z;Coudert B;Waterhouse D;Waller C;Kubota K;Vrindavanam N;Malcolm A;Palmero Sanchez R;Juergens R;Jassem J;Chachoua A;Feld R;Bradbury P;Azuma K;Kemmotsu H;Aglietta M;Scholz C;Canon J.-L;Weiss G;Bosch-Barrera J;Goto K;Vincent M;Sakai H;Denis F;Hsia T.-C;Chih-Hsin Yang;Alvarez Alvarez R;Garcia Gomez R;Chewaskulyong B;Spigel D;Chen Y.-M;Barlesi F;Kowalski D;Italiano A;Lucien Geater S;Uy M.N;Santoro A;Kubiak K;Zylla D;Maeda T;Derijcke S;Veillon R;Gabrail N;Imamura F;Nishio M;Spaeth-Schwalbe E;Atagi S;Kang E.J;Yokoi T;Sibille A;Ramos Garcia I;Milella M;Saka H;Lee J.-S;Wolf J;Kim Y.-C;Su W.-C;Katakami N;Atlantic Investigators;Szalai Z;Garrison M;Overton L;Cheema P;Thomas M;Soto Parra H;Robinet G;Chopra A;Chella A;Oe Y;Belda Iniesta C;Holgado Martin E;Han J.-Y;Reck M;Surmont V;Kim D.-W;Berghmans T;Vicente Baz D;Chaft J;Kim S.-W;Maemondo M;Califano R;Laack E;Schmid P;Hiret S;Novello S;Paz-Ares Rodriguez L;Rizvi N.A;Dennis P.A;Wadsworth C;Huang Y;Soo R.A;Park K;Wheatley-Price P;Bidoli P;Chouaid C;Powderly J;Gray J.E;Corral Jaime J;Lena H;Vansteenkiste J;Mazi?res J;Kim J.-H;Cho B.-C;Garassino M.C |
| 臺大學術典藏 |
2020-05-26T09:26:27Z |
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
|
Park K.;Paz-Ares L; Chih-Hsin Yang;M?rten A;Peil B;Mok T;Boyer M;O'Byrne K;Yamamoto N;Hirsh V;Schuler M;Barrios C.H;Kato T;Tsai C.-M;Lee K.H;Zhang L;Orlov S;Geater S.L;Tan E.-H;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Tan E.-H; Geater S.L; Orlov S; Zhang L; Lee K.H; Tsai C.-M; Kato T; Barrios C.H; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin CHIH-HSIN YANG; Paz-Ares L; Park K. |
